We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
-7.92%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$443M
AUM Growth
-$5.44M
Cap. Flow
-$82.1M
Cap. Flow %
-18.51%
Top 10 Hldgs %
47.3%
Holding
81
New
8
Increased
12
Reduced
20
Closed
11

Top Buys

Rank Stock Value
1
NVAX icon
Novavax
NVAX
+$11.8M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$8.15M
3
RARE icon
Ultragenyx Pharmaceutical
RARE
+$6.61M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$6.34M
5
UTHR icon
United Therapeutics
UTHR
+$3.81M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$17.9M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$13.7M
3
GILD icon
Gilead Sciences
GILD
+$12.4M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$12.4M
5
BIIB icon
Biogen
BIIB
+$11.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.53%
2 Miscellaneous 0.47%
3 Utilities 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FATE icon
26
Fate Therapeutics
FATE
$304M
$5.64M 1.27%
28,000
– –
LEGN icon
27
Legend Biotech
LEGN
$3.99B
$5.63M 1.27%
4,500
– –
AXSM icon
28
Axsome Therapeutics
AXSM
$10.8B
$5.4M 1.22%
+14,000
New +$434K
MDGL icon
29
Madrigal Pharmaceuticals
MDGL
$12.6B
$5.07M 1.14%
+5,350
New +$451K
KDNY
30
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$4.71M 1.06%
340,389
+51,000
+18% +$693K
AUPH icon
31
Aurinia Pharmaceuticals
AUPH
$2.19B
$3.96M 0.89%
435,000
+100,500
+30% +$1.55M
IONS icon
32
Ionis Pharmaceuticals
IONS
$10.4B
$3.3M 0.74%
154,088
-201,000
-57% -$6.58M
VRTX icon
33
Vertex Pharmaceuticals
VRTX
$139B
$3.23M 0.73%
25,122
-52,100
-67% -$12.4M
XENE icon
34
Xenon Pharmaceuticals
XENE
$6B
$3.2M 0.72%
25,500
– –
NBIX icon
35
Neurocrine Biosciences
NBIX
$15.8B
$3.15M 0.71%
203,000
-77,000
-28% -$6.53M
UTHR icon
36
United Therapeutics
UTHR
$22.6B
$2.94M 0.66%
+20,000
New +$3.81M
IOVA icon
37
Iovance Biotherapeutics
IOVA
$3.74B
$2.84M 0.64%
58,000
– –
HARP
38
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$2.77M 0.62%
15,145
-6,355
-30% -$329K
INCY icon
39
Incyte
INCY
$25.9B
$2.58M 0.58%
238,000
-47,000
-16% -$3.42M
NBP
40
NovaBridge Biosciences American Depositary Shares
NBP
$219M
$2.38M 0.54%
18,000
– –
REGN icon
41
Regeneron Pharmaceuticals
REGN
$83.2B
$2.25M 0.51%
12,100
– –
RARE icon
42
Ultragenyx Pharmaceutical
RARE
$2.59B
$2.07M 0.47%
233,100
+95,000
+69% +$6.61M
ASND icon
43
Ascendis Pharma A/S
ASND
$16.4B
$1.95M 0.44%
29,400
– –
GBT
44
DELISTED
Global Blood Therapeutics, Inc.
GBT
$1.64M 0.37%
151,800
+57,000
+60% +$1.7M
IDYA icon
45
IDEAYA Biosciences
IDYA
$4.03B
$1.62M 0.37%
109,000
– –
TVTX icon
46
Travere Therapeutics
TVTX
$6.36B
$1.55M 0.35%
380,000
– –
APLS
47
DELISTED
Apellis Pharmaceuticals
APLS
$1.54M 0.35%
32,500
– –
SWTX
48
DELISTED
SpringWorks Therapeutics
SWTX
$1.38M 0.31%
16,300
-8,700
-35% -$498K
MRTX
49
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$1.37M 0.31%
188,500
+62,000
+49% +$6.34M
CCXI
50
DELISTED
ChemoCentryx, Inc.
CCXI
$1.31M 0.3%
36,100
– –
1
2
3 4

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q1 2022 Portfolio in Review

As of Q1 2022, International Biotechnology Trust held 81 positions worth $443M, down 1.2% from $449M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

International Biotechnology Trust withdrew a net $82.1M in Q1 2022, closing 11 positions and reducing 20 holdings. Its most notable exit was Biogen, an estimated $11.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier, followed by Miscellaneous and Utilities.

Against the trend, International Biotechnology Trust opened a new position in Novavax worth $18.5M.

  • International Biotechnology Trust's largest Q1 2022 buy was Novavax: 132,500 shares worth $18.5M.
  • International Biotechnology Trust added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2022, an estimated $8.15M increase.
  • International Biotechnology Trust's biggest Q1 2022 reduction was Amgen, cutting an estimated $17.9M.
  • International Biotechnology Trust fully exited Biogen in Q1 2022, selling an estimated $11.4M.
  • International Biotechnology Trust's ten largest holdings make up 47% of its $443M portfolio in Q1 2022.
  • International Biotechnology Trust opened 8 new positions and closed 11 in Q1 2022.
  • International Biotechnology Trust's portfolio value fell 1.2% quarter-over-quarter to $443M.

Based on International Biotechnology Trust's 13F filing for Q1 2022, filed 20 May 2022.